Company

Peloton Therapeutics, Inc.

Peloton Therapeutics develops cancer drug candidates that target HIF-2a.

About

Peloton Therapeutics develops medicines targeting HIF-2a, with a focus on renal cell carcinoma and von Hippel-Lindau disease. The company was founded in 2010 and is based in Dallas, US. Merck acquired Peloton in May 2019 for USD 1.05 billion in cash, plus potential milestone payments totaling up to USD 1.15 billion.

5Funding rounds

13Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in